Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp V.KHRN.H

Alternate Symbol(s):  KHRNF | KHRWF | V.KHRN.WT.H

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Benedictuson Nov 10, 2020 12:17am
181 Views
Post# 31868407

RE:RE:RE:Whoever requested a halt this morning should be fired

RE:RE:RE:Whoever requested a halt this morning should be fired

The company just announced in their last corporate update that they had $14.7M at the end of Q3 but also showed that the cash burn bumped up from $4M in Q2 to $5.3M, which was not insignificant. Assuming a similarly high burn for Q4 and Q1 would have puts them out of cash by Q2 (about the time management had stated many times they'd expected to be cash neutral).

My guess is they're going to blame this surprise pp partly on Covid but I am starting to believe their strategy of asset lite entry into fiercely competitive markets is offering lower margins, operational challenges due to covid and less top line growth than they'd expected. 

This pp if they get the over allotment and assuming full warrant conversion just bloated the sharecount by over 50% and it buys them slightly more than 2 quarters of cash to burn. I will tune into the webcast but unless they absolutely wow me with their plans for this capital I will be looking for an exit. 

<< Previous
Bullboard Posts
Next >>